OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:01 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation

NCT03031470 · Dompé Farmaceutici S.p.A · PHASE2 · terminated · last registry update 2025-01-07 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Taking into account that 5 out of 22 patients in the Reparixin group experienced EAD during the first stage of the study, according to the Protocol and the DMC conclusion, it was decided on the early termination of the study”–Registry record, Dompé Farmaceutici S.p.A

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against CXCR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision